RBP-6000, a new Atrigel-based monthly subcutaneous long-acting formulation of buprenorphine

First published: 13/03/2019 | Last updated: March 28th, 2019

{alt_text}

Dr Chris Bushe

NEU Medical Director

Dr Bushe qualified from St Georges’s medical school in 1981. He worked in acute medical specialities (ITU and cardiology) and went on to train in psychiatry. For the last 20 years he has worked in the pharmaceutical industry in the areas of schizophrenia, ADHD, bipolar disorder and most recently addiction.  He joined Indivior in 2017 as North European Medical Director. In his career he has authored over 60 publications and 4 book chapters and given lectures worldwide. His scientific interests include the accurate reporting of clinical data in an interpretable manner, the trajectory of changes within clinical trials and the increasingly critical development of long acting injections in many CNS and neurological disorders. He tries to retain his sanity through football (Brentford FC) and photography. Chrisbushephotography.com



RBP-6000 is a long acting injection of buprenorphine currently in development designed to provide therapeutic plasma levels of buprenorphine consistently from the first month of treatment. Data in Opioid Use Disorder will be presented from a 24 and 52 week clinical trials. Endpoints presented will include abstinence rates, categorical and variable, tolerability and safety.

 

Dr Chris Bushe